PIPELINE

DRUG DISCOVERY PIPELINE

Through the tight integration of our platform, team and external capabilities, we are moving multiple programs towards the clinic and closer to our vision of delivering better medicines to the right patients. Once the SMarTR Engine has identified diseases with subpopulations and/or novel targets, Auransa is then able to initiate research and development programs to meet those needs.

What sets our platform apart:
  • Ability to move from molecular data to disease subpopulations and hits in 2-3 weeks
  • High validation rate – 50% on average – when predicted hits are tested in in vitro, in vivo and ex vivo assays across various therapeutic areas
  • Subtype-driven approach accelerates timeline to preclinical studies on novel compounds

SMarTR ENGINE-IDENTIFIED DISEASES WITH SUBPOPULATIONS AND/OR NOVEL TARGETS

Pipeline legend

PIPELINE OF NOVEL DRUGS 
MOVING TOWARDS IND

Auransa Pipeline

CANCER

PRECLINICAL

  • Hepatocellular carcinoma (HCC

DISCOVERY

  • Acute myeloid leukemia (AML)

  • Breast cancer

  • Multiple myeloma

  • Prostate cancer

  • Small cell lung cancer (SCLC)

CANCER SUPPORTIVE CARE

PRECLINICAL

  • Cardioprotection
INFECTIOUS DISEASE

DISCOVERY

  • Gram negative bacteria

INFLAMMATION & IMMUNOLOGY

DISCOVERY

  • Rheumatoid arthritis
METABOLIC DISEASES

DISCOVERY

  • NASH
NEUROSCIENCE

DISCOVERY

  • Alzheimer’s Disease